Gilead Sciences
FY2025 revenue $29.4B; 2026 guidance $29.6-30.0B driven by HIV franchise (Yeztugo projected $800M in 2026 vs $150M in 2025). Committed $32B U.S. investment through 2030 including an AI-enabled biologics development center. AI partnerships with Genesis Therapeutics ($35M) and Terray Therapeutics for ML-driven drug discovery.
Scenarios
Yeztugo growing 5x from 2025 to 2026. Long-dated IP on Biktarvy plus oncology pipeline create a durable $30B+ revenue floor that AI R&D efficiencies strengthen.
Core HCV franchise structurally declining. AI drug discovery partnerships are exploratory — no AI-originated molecule is in Phase 3. If Biktarvy faces biosimilar competition before 2033, AI cannot fill the gap.
Key Factors to Watch
- ●Yeztugo HIV prevention revenue trajectory ($150M→$800M) is the key 2026 growth metric
- ●AI biologics center is 10-year infrastructure, not near-term revenue
- ●Genesis/Terray partnerships expand shot volume but typical AI→approval timeline is 8-12 years
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 5.8 | Neutral | Score 5.9→5.8 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 5.9 | Neutral | Initial assessment from batch 9 blind spot review |
Healthcare Peers
Last researched: 2026-03-16
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.